A randomized, open-label trial of combined nitazoxanide and atazanavir/ritonavir for mild to moderate COVID-19

A randomized, open-label trial of combined nitazoxanide and atazanavir/ritonavir for mild to moderate COVID-19

BackgroundThe nitazoxanide plus atazanavir/ritonavir for COVID-19 (NACOVID) trial investigated the efficacy and safety of repurposed nitazoxanide combined with atazanavir/ritonavir for COVID-19.MethodsThis is a pilot, randomized, open-label multicenter trial conducted in Nigeria. Mild to moderate CO...

Full description

Bibliographic Details
Main Authors: Adeola Fowotade, Folasade Bamidele, Boluwatife Egbetola, Adeniyi F. Fagbamigbe, Babatunde A. Adeagbo, Bolanle O. Adefuye, Ajibola Olagunoye, Temitope O. Ojo, Akindele O. Adebiyi, Omobolanle I. Olagunju, Olabode T. Ladipo, Abdulafeez Akinloye, Adedeji Onayade, Oluseye O. Bolaji, Steve Rannard, Christian Happi, Andrew Owen, Adeniyi Olagunju
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-09-01
Series:Frontiers in Medicine
Subjects:
COVID-19
SARS-CoV-2
nitazoxanide (NTZ)
atazanavir/ritonavir
pharmacokinetics
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2022.956123/full

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2022.956123/full

Similar Items